press release

May 5, 2017

Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development ProgramCAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 5, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it will advance a systemically delivered RNAi therapeutic for the treatment of hypercholesterolemia as its next clinical development program. This program, in collaboration with ...

press release

May 5, 2017

Alnylam to Webcast its R&D Day on Tuesday, December 5, 2006CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 29, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its R&D Day presentation will be webcast live on the "Investors" section of the company's website at www.alnylam.com. Alnylam's management, scientists, and other invited speakers will review the company's research ...

press release

May 5, 2017

Alnylam Grants Eurogentec License to Fundamental RNAi Patents in the Research Products MarketCAMBRIDGE, Mass. & SERAING, Belgium (BUSINESS WIRE) July 12, 2005 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has granted Eurogentec, a leading provider of genomics research solutions, a non exclusive license to provide research products and services in RNA interference (RNAi) under ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 9, 2005 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended September 30, 2005, and company highlights. "Our progress over the last four months has propelled Alnylam significantly forward in our mission to build a leading product company founded on RNAi," said John Maraganore, ...

press release

May 5, 2017

Alnylam to Webcast its R&D Day on Wednesday, December 14, 2005CAMBRIDGE, Mass., Dec 07, 2005 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its R&D Day presentation will be webcast live on the "Investors" section of the company's website at www.alnylam.com. Alnylam's management, scientists, and other invited speakers will review the company's research ...

press release

May 5, 2017

.bwtextaligncenter {text align: center} CAMBRIDGE, Mass., Feb 22, 2010 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients ...

press release

May 5, 2017

Alnylam Announces Pandemic Flu as Next Development Program; Obtains Initial Federal Funding to Develop RNAi Therapeutics for Pandemic Influenza and Identifies Dowpharma(SM) as Potential Source for Domestic ManufacturingCAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 14, 2005 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its decision to advance its pandemic flu project as a development program, adding to the ...